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Abstract 
Purpose  To assess the prognostic factors of resection of intrahepatic cholangiocarcinoma 
(IHCC), which remain unclear. 
Methods  Among 70 patients with IHCC, who were admitted to our hospital between 1998 
and 2011, 45 (64%) underwent resection and 25 had unresectable tumors. Univariate and 
multivariate analyses were conducted retrospectively to assess the factors influencing 
survival of the patients who underwent resection.  
Results  The median survival times of the patients who underwent resection versus those 
who did not were 16 and 9 months, respectively (P < 0.001). Multivariate analysis identified 
residual tumor status (relative risk, 4.12; P = 0.04) and pathological differentiation (relative 
risk, 5.55 P = 0.04) as independent factors predicting survival. Patients who underwent R1 
resection had a significantly higher rate of local recurrence than those who underwent R0 
resection (P = 0.008). With R0 resection, there were no significant differences in patterns and 
rates of recurrence between patients with narrow (≤ 5 mm) versus wide (> 5 mm) surgical 
margins. 
Conclusions  R0/1 resection and well-differentiated tumor were found to be independent 
prognostic factors for long-term survival after IHCC resection. If R0 resection was achieved, 
the width of the negative surgical margin did not affect the patterns and rates of recurrence.  
 Key word  Intrahepatic cholangiocarcinoma, prognostic factor, surgical resection 
Introduction 
 
Intrahepatic cholangiocarcinoma (IHCC) is the second most frequent primary liver cancer, 
but accounts for only 4.1% of all patients with primary liver cancer, according to a nationwide 
survey conducted in Japan [1]. The most effective treatment for IHCC is potentially curative 
resection, with a 5-year survival rate of approximately 20% [2]. One major reason for the 
dismal prognosis is the lack of predictive markers for the disease, but the effects of the 
surgical procedures used and other factors affecting the survival of patients with IHCC after 
resection have not been fully elucidated. 
Several prognostic factors for IHCC have been reported. A few studies have 
identified lymph node metastasis as one of the most important [3-5], while others have 
proposed positive surgical margins and intrahepatic metastasis as key factors predicting 
poor outcomes after surgical resection [6]. Serum tumor markers have also been recognized 
as important prognostic factors [7-10], although some authors have reported that these 
factors did not affect the survival of IHCC patients [11]. We conducted the current study to 
define the factors influencing prognosis after surgical resection based on our 13-year 
experience of patients with IHCC treated in our hospital. 
 
Methods 
 Patients 
 
The subjects of this retrospective study were 70 patients admitted to Kobe University 
Hospital, Japan, between July 1998 and April 2011, for management of peripheral IHCC . 
Peripheral IHCC was defined as a tumor that had developed from the intrahepatic bile duct 
at a site peripheral to the second branch. This study did not include patients with combined 
hepatocellular and cholangiocellular carcinoma or those with cholangiolocellular carcinoma. 
Prior to surgery, all patients provided informed consent to have relevant data from their 
medical records used in clinical studies, if appropriate. 
Of the 70 patients, 15 had inoperable disease, based on radiologic examinations. The 
reasons for inoperability were multiple liver metastases (n = 2), lung metastasis (n = 2), 
locally invasive tumor (n = 7), and poor general condition (n = 4). The remaining 55 patients 
were scheduled for surgical resection; however, during surgery, 10 of these  patients were 
found to have unresectable disease, such as peritoneal metastasis (n = 6), invasion of the 
inferior vena cava (n = 2), multiple liver metastases (n = 1), or severe adhesions after 
gastrectomy (n = 1). The resectability rate was 64.3% (45/70). 
Predictive factors were examined in 44 patients, thus excluding 1 patient who died 
during the postoperative stay in hospital. The following characteristics were obtained from 
medical records, reviewed and analyzed: carcinoembryonic antigen (CEA), carbohydrate 
antigen (CA) 19-9, number of tumors, tumor size (diameter), pathological differentiation, T 
category, N category, and residual tumor status. Tumor staging was based on the American 
Tumor Study Group modified Tumor-Node-Metastases (TNM) Staging Classification, 7th 
edition [12]. 
 
Surgery for IHCC   
 
Forty-five patients underwent surgical resection, at the time of which, sampling of regional 
or paraaortic lymph nodes was routinely performed. N category was classified based on the 
histological result of sampling lymph nodes or imaging studies. Residual tumor status was 
defined as follows: R0 resection, no macroscopic or microscopic tumor remaining; R1 
resection, microscopically positive surgical margins; and R2 resection, not all gross tumors 
removed.  
After surgery, patients received regular clinical follow-up with blood chemistry, 
including the tumor markers CA 19-9 and CEA. They were examined for recurrence at 3-6 
monthly intervals by computed tomography (CT) scans of the abdomen and lungs. 
Recurrence was diagnosed mainly based on the imaging studies. 
 
Chemotherapy for IHCC  
 
Postoperative adjuvant chemotherapy was given to selected patients after R0 or R1 resection, 
who had poor prognostic factors such as lymph node metastasis. Patients with R2 resection 
were excluded from the analysis of adjuvant chemotherapy. We started treatment with 
gemcitabine (GEM) within 10 weeks after surgery. For this adjuvant therapy, six cycles of 
GEM were planned, with each 28-day cycle consisting of intravenous GEM administered at a 
dose of 1000 mg/m2 on days 1, 8, and 15, and withdrawal of GEM on day 22. If adverse events 
of grade 3 or 4 were observed, the cycle was usually changed to biweekly scheduling. Adverse 
events were assessed according to the US National Cancer Institute Common Toxicity 
Criteria scale (version 2.0) [13]. Of the 39 patients who underwent R0 or R1 resection, 15 
(38%) received adjuvant chemotherapy with GEM. 
Of the five patients who underwent R2 resection, two received GEM-based 
chemotherapy, one received 5-fluorouracil-based chemotherapy, and two received 
palliative care. For the 25 patients with unresectable disease, 17 received GEM-based 
chemotherapy, 1 underwent transcatheter arterial chemoembolization, and 7 received 
palliative care.  
 
Statistical Analysis 
 
The χ2 test was used to compare categorical variables in the study patients with IHCC. 
Survival curves were constructed using the Kaplan-Meier method and the log-rank test was 
used to compare the curves. Cox proportional hazard models were used to estimate relative 
risks and 95% confidence intervals. Multivariate analysis was performed for factors that were 
significantly associated with survival in univariate analysis. Differences were considered 
significant at P < 0.05. Statistical analysis was performed using JMP software, 9th edition 
(SAS, Cary, NC, USA). 
 
Results 
 
Patient Characteristics 
 
Table 1 summarizes the patients’ characteristics. The 70 patients analyzed included 44 men 
and 26 women with a median age of 68 years. In terms of virus status, six patients were 
positive for anti-hepatitis C virus antibody (anti-HCV), five were positive for hepatitis B 
surface antigen (HBs-Ag), and two were positive for both anti-HCV and HBs-Ag. Indocyanine 
green (ICG) tests were performed for 27 patients and the mean retention rate of ICG 15 min 
after administration (ICG-R15) was 11.3%. There were no patients with cirrhosis in this 
series. 
Of the 45 patients who underwent resection, 17 (38%) had experienced symptoms, as 
follows: upper abdominal pain (n = 9), general fatigue (n = 3), and other symptoms such as 
anorexia, epigastric discomfort, epigastric tumor, weight loss, and jaundice (n = 5).  
 
Surgical Procedures and Mortality 
 
The surgical procedures are listed in Table 1. Twenty-eight patients underwent R0 resection, 
12 underwent R1 resection, and 5 underwent R2 resection. Of the 12 patients who underwent 
R1 resection, there was residual tumor at the bile duct stump in 3 patients, in the liver 
parenchyma in 7 patients, and both of these locations in 2 patients. One patient with R1 
resection died of pneumonia during the postoperative stay, resulting in a hospital mortality 
rate of 2% (1/45). The study analyses were performed using clinical data from the remaining 
44 patients.  
 Tumor Markers 
 
CEA and CA19-9 concentrations were measured in all except 1 of the 44 patients analyzed. 
CEA was elevated in 14 patients, with a median value of 3.2 ng/ml (range, 0.8-1392 ng/ml; 
reference value, < 5 ng/ml). CA19-9 was elevated in 24 patients, with a median value of 52.8 
U/ml (range, 2-829,290 U/ml; reference value, < 37 U/ml). To examine the prognostic 
importance of CA19-9, patients were divided into two groups according to the CA19-9 cut-off 
point specified in a previous report, of ≥ 200 U/ml and < 200 U/ml [14]. Of the 43 patients 
with tumor marker measurements, 21 had CA19-9 ≥ 200 U/ml. All of the patients with R2 
resection had an elevated CA19-9 ≥ 200 U/ml. 
 
Tumor Characteristics 
 
According to the morphologic classification of the Liver Cancer Study Group of Japan criteria, 
there were 38 patients with mass-forming type (MF), 2 with intraductal growth type (IG), 2 
with MF + IG type, and 2 with periductal infiltrating type IHCC. The mass-forming type was 
dominant and there were eight patients with multi-nodular tumors. The mean tumor 
diameter was 6.1 cm (range, 1.8-15 cm). Pathologically, the tumors were diagnosed as well 
differentiated adenocarcinoma in 9 patients, moderately differentiated adenocarcinoma in 29 
patients, poorly differentiated adenocarcinoma in 1 patient, adenosquamous cell carcinoma 
in 2 patients, and unknown differentiated carcinoma in 3 patients. Twenty-one patients had 
microscopic vascular invasion and 11 had lymph node metastasis. According to the TNM 
staging system, the overall stage was classified as I in 11 patients, II in 18 patients, III in 4 
patients, and IV in 11 patients. 
 
Analyses of Survival and Recurrence 
 
The median survival times of the patients who underwent resection versus those who did not 
undergo resection were 16 months versus 9 months, respectively, with a median observation 
period of 11 months (P < 0.0001). The 5-year survival rate of the patients who underwent 
resection was 41.8%, with one patient surviving > 8 years, while the longest survival time 
among the patients who did not undergo resection was only 27 months (Fig. 1). 
Recurrence developed in 22 of the 39 (56%) patients who underwent R0 or R1 resection. 
Univariate and multivariate analyses were performed using data from the 44 patients who 
underwent resection, excluding the R1 resection patient who died in hospital; for CEA and 
CA19-9 analyses. An additional patient without measurements was also excluded (Table 2). 
Based on univariate analysis, CA19-9 < 200 U/ml, well differentiated adenocarcinoma, T1 or 
T2 tumors, and R0 or R1 resection were significant prognostic factors. The N category did not 
have an impact on survival. We also examined the patients who did not undergo bile duct 
resection, because the efficacy of bile duct resection for lymphadenectomy was still 
controversial [2,15]. We found the  N category did not have an impact on survival (RR 1.45, 
P = 0.54). Multivariate analysis revealed that residual tumor status and pathological 
differentiation were the only variables significantly related to survival. GEM-based adjuvant 
chemotherapy did not improve either the cumulative or disease-free survival rates. 
Next, we examined the cut-off point of the serum CA 19-9 level using the receiver 
operating characteristic (ROC) curve (Fig 2a). The cut-off point was 625 U/ml. The ROC 
curve was generated for the death during the observation period. The area under the ROC 
curve was 0.71. CA19-9 was over 625 U/ml in 14 patients. The 2-year survival rates of 
patients whose CA19-9 was < 625 U/ml versus those whose CA19-9 was ≥625 U/ml were 82 
and 0 %, respectively (Fig.2b). 
Fig. 3 shows survival according to the residual tumor status. R0 resection tended to 
result in a better prognosis (cumulative survival) than R1 resection, but the difference was 
not significant (P = 0.18). The cumulative survival rate of patients who underwent R2 
resection was worse than those of the patients who underwent R0 (P < 0.0001) or R1 
resection (P = 0.002) (Fig. 3a). Lymph node metastasis was detected in 21% (6/28) of patients 
who undewent R0 resection and in 9% (1/11) of those who underwent R1 resection (P = 0.34). 
There was no statistically significant difference in disease-free survival between patients 
who underwent R0 versus those who underwent R1 resection (P = 0.33) (Fig. 3b). 
 
Recurrence and Margin Status 
 
Next, we examined the relationship between cancer recurrence pattern (sites) and surgical 
margin status, because the survival of patients with IHCC has been reported to correlate 
strongly with surgical margin status [16]. The negative margin width was examined in 28 
patients who underwent R0 resection. The median margin width was 1 mm (range, 0 - 40 
mm), and only five patients had margins > 10 mm. Table 3 shows the initial recurrence sites 
and negative surgical margin widths, including the site of distant recurrence. Local 
recurrence was defined as a tumor that recurred within 10 mm from the surgical margin. The 
rate of local recurrence was higher in patients with R1 resection (55%, 6/11) than in those 
with R0 resection (11%, 3/28) (P = 0.008). With regard to surgical margin width, patients with 
margins ≤ 5 mm versus > 5 mm showed similar patterns and rates of recurrence (P = 0.93). In 
patients with R0 resection, there was no significant difference in either the disease-free 
survival rate (44 % vs. 42 %, P = 0.87) or cumulative survival rate (63% vs. 75%, P = 0.77) at 3 
years between patients with narrow (≤ 5 mm) versus wide (> 5 mm) margins, respectively. 
 
Discussion 
 
The prognosis of patients with resected IHCC remains unsatisfactory despite progress in 
aggressive surgical treatments [2]. After surgical resection, the reported recurrence rate is 
55-72% [7-10,17-20]. The current study showed a similar recurrence rate (56%). A possible 
reason for the poor prognosis may be the lack of a standardized optimal surgical protocol for 
resecting IHCC. For example, the need for lymphadenectomy and adequate surgical margin 
width remains to be determined. Therefore, we examined the prognostic factors and the 
impact of a negative surgical margin width in patients with resected IHCC, based on our 
13-year experience. We confirmed that residual tumor status (R0/1 resection) is an important 
predictor of long-term survival. 
Curative surgical resection is the most effective treatment for IHCC. The beneficial 
impact of R0 resection is completely recognized; however, the influence of R1 resection on 
survival is controversial. Several published reports have suggested that R1 resection is an 
important prognostic factor associated with poorer survival [3,4,8,21-24]. In this study, the 
survival of patients who underwent R0 or R1 resection was significantly better than that of 
those who underwent R2 resection. While the survival rate of patients who underwent R0 
resection tended to be higher than that of those who underwent R1 resection, the difference 
did not reach statistical significance, probably due to the small patient numbers. Another 
reason for this result may be the higher rate of lymph node metastasis in patients who 
underwent R0 resection (21%) than that in those who underwent R1 resection (9%). Different 
rates of lymph node metastasis might make the survival curve of R0 patients more closely 
match that of R1 patients, because lymph node metastasis is recognized as a powerful 
prognostic factor [3-5]. In this study, the overall rate of lymph node metastasis in the patients 
who underwent resection was 25%, similar to that reported in previous papers (14-40%) 
[4,5,16,24]. Interestingly, recent reports suggest that for patients without lymph node 
metastasis, a positive surgical margin is an important prognosis factor, althoug for patients 
with lymph node metastasis, a positive margin is not a prognostic factor [3,16]. Our results 
clearly demonstrated that R1 resection is associated with a better prognosis than R2 
resection; therefore, R1 resection could be appropriate when R0 resection cannot be achieved. 
We examined surgical margin width in patients with R0 resection because the influence 
of resection margin on outcome has also been controversial. Patients with narrow or wide 
negative margins showed similar recurrence patterns, reflecting the results of previous 
papers [10,25,26]. In contrast, a recent paper reported that margin width and prognosis 
correlated linearly in patients without lymph node metastasis, and > 10 mm could be 
considered a safe surgical margin [16]. Other papers similarly suggested that curative 
resection requires a clear margin of 10 mm [14,27]. With regard to surgical margins, there is 
an interesting report that mutations of the APC or KRAS gene were detected even 4 mm 
from the macroscopic tumor border in patients with liver metastasis of colorectal 
adenocarcinoma [28]. This finding raises the possibility that tumor may remain in cases of a 
narrow margin width. However, a multi-institutional analysis recently showed that survival 
was not influenced by the width of a negative resection margin [29]. 
While there were many cases of local recurrence with R1 resection, the most common 
sites of recurrence after R0 resection were distant in this study. Shimada et al. [25] and 
Tamandl et al. [10] also reported that residual tumor status (R0 or R1) did not correlate with 
the recurrence site and that there were distant metastases, such as in the liver or lymph 
nodes. This suggests that resection should be performed even if a wide negative margin is 
difficult to achieve. 
The current study did not confirm the impact of lymph node metastasis on survival. 
This atypical finding is probably because of the different surgical procedures used for 
sampling of the lymph nodes, without performing systematic lymphadenectomy. The 
significance of systematic lymphadenectomy is still unknown. Previous reports have 
indicated that lymphadenectomy improved survival, with findings based on the macroscopic 
classification or the numbers or sites of lymph node metastases [22,30,31]. However, only a 
few reports have compared the survival of patients with IHCC with lymphadenectomy versus 
without lymphadenectomy [2,15,24]. These reports concluded that routine systematic 
lymphadenectomy is of limited value and do not recommend it. Further prospective studies 
are required to resolve this issue. 
Our univariate analysis revealed that elevated CA19-9 is an important prognostic 
factor after surgical resection, as suggested in other recent reports [7-10]. However, when 
examining the prognostic value of CA19-9, various investigators used different cut-off point 
for CA19-9 [9,10,19]. In the current study, we set the cut-off for CA19-9 at 200 U/ml, 
consistent with the report by Cho et al. [14]. If we had used a CA19-9 cut-off of ≥ 625 U/ml, 
which was found by ROC analysis, the 2-year survival rate for our patients with this more 
highly elevated CA19-9 would have been 0%. We used the 200U/ml for the cut-off point of 
CA19-9 for multivariate analysis in this study because too few patients had a CA19-9 level ≥
625U/ml. In contrast, some investigators reported that CA19-9 was not a prognostic factor 
based on setting the CA19-9 cut-off at 37 or 40 U/ml [7,32,33]. Because a previous study 
found that CA19-9 was associated with tumor size and lymph node metastasis [23], an 
extremely high CA19-9 level may be suggestive of progression like lymph node metastasis or 
dissemination. 
Another factor predicting survival was pathological differentiation. However, we were 
only able to confirm this after surgery and surgeons do not remedy it. If the histological 
diagnosis based on preoperative biopsy is not well differentiated adenocarcinoma, patients 
could be a candidate for neo-adjuvant chemotherapy. However, the risk of dissemination was 
previously reported [34]. We should positively consider adjuvant chemotherapy for these 
patients because their prognosis is poor, although there are very few reports about adjuvant 
treatment for IHCC. In the present study, selected patients received chemotherapy with 
GEM, but our retrospective analysis did not show that GEM had a significant impact on the 
survival of patients with resected IHCC. Shinohara et al. [35] reported that adjuvant 
radiation therapy after surgery could improve median overall survival compared with 
surgery or radiation alone. Murakami et al. [36] reported that GEM-based adjuvant 
chemotherapy was effective for cholangiocarcinoma, including IHCC. Shen et al. [37] found 
that adjuvant transcatheter arterial chemoembolization with fluorouracil or carboplatin, 
epirubicin, and hydroxycamptothecin did not improve recurrence-free survival, but it 
prolonged overall survival. Although further prospective investigation is required, our data 
suggest that a drug other than GEM or combination chemotherapy should be considered for 
patients with resected IHCC. 
This study has some limitations. It was retrospective and the sample size was small. 
Moreover, we did not perform systematic lymphadenectomy and there may be a selection 
bias in adjuvant chemotherapy. Therefore, further studies on a large number of patients are 
necessary to evaluate the prognostic factors about IHCC more accurately. 
In conclusion, residual tumor status and pathological tumor differentiation are 
significant prognostic factors for long-term survival after resection of IHCC. R0/1 resection 
can improve the survival of patients with IHCC. R1 resection was associated with a higher 
risk of local recurrence than R0 resection. In R0 resection, negative surgical margin width 
did not affect the patterns and rates of recurrence, so these patients should be carefully 
monitored for possible distant metastasis, rather than just local recurrence, during follow-up.  
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 Figure legends 
Fig. 1 Kaplan-Meier cumulative survival curve for patients with intrahepatic 
cholangiocarcinoma (IHCC) to evaluate surgical resection versus no surgical resection. P < 
0.0001.  
Fig. 2 a Receiver operating characteristic (ROC) curve based on CA19-9. The area under the 
ROC curve was 0.7. b Kaplan-Meier survival curve based on the CA19-9. P <.0001. 
Fig. 3 a Kaplan-Meier cumulative survival curve based on the residual tumor status. P = 0.15 
for R0 versus R1, P = 0.0001 for R0 versus R2, and P = 0.005 for R1 versus R2. b 
Kaplan-Meier disease-free survival curve based on the residual tumor status. P = 0.42.
 BDR, bile duct resection. 
Table 1  Patient characteristics and surgical procedures performed for intrahepatic 
cholangiocarcinoma (IHCC) 
Characteristics 
 
Total Resected  
n = 45 
Unresected  
n = 25 
Sex (n), male/female 44/26 30/15 14/11 
Age (years), median (range) 68 (38-86) 67 (45-86) 69 (38-86) 
Viral status (n)    
Anti-HCV(-) and HBs-Ag(-) 55 35 22 
Anti-HCV(+) and HBs-Ag(-) 6 5 1 
Anti-HCV(-) and HBs-Ag(+) 5 4 1 
Anti-HCV(+) and HBs-Ag(+) 2 1 1 
ICG-R15 (%), mean (range) 11.3 (3.5-22.5) 10.9 (4.9-22.5) 12.6 (3.5-21) 
Operation (n)    
Left major hepatectomy (+ BDR)  20 (1)  
Right major hepatectomy (+ BDR)  10 (1)  
Hepatic segmentectomy  11  
Partial hepatectomy  4  
 RR, relative risk; CI, confidence interval; UICC, Union for International Cancer Control. 
Table 2  Univariate and multivariate analyses 
Clinicopathological 
factors 
 Univariate analysis  Multivariate analysis 
n RR (95% CI) P-value  RR (95% CI) P-value 
Sex      
 Male 30      
  Female 14 1.43 (0.53-3.57) 0.46    
CEA (ng/ml)      
  < 5 29      
  ≥ 5 14 1.84 (0.67-4.73) 0.22    
CA19-9 (U/ml)      
  < 200 22      
  ≥ 200 21 3.61 (1.19-10.47) <.0001  3.35 (1.07-11.7) 0.037 
Tumor number      
  1 36      
  ≥ 2 8 1.10 (0.25-3.33) 0.87    
Tumor size (cm)      
  < 4.5 21      
  ≥ 4.5 22 1.67 (0.65-4.56) 0.27    
Pathological differentiation      
  Well 9      
  Others 35 6.41 (1.30-115.97) 0.017  5.55 (1.03-103) 0.045 
UICC T classification      
  T1,2 38      
  T3,4 6 3.41 (1.08-9.19) 0.037  2.60 (0.60-9.77) 0.18 
UICC N classification      
  N0 23      
  N1 11 0.94 (0.26-2.63) 0.91    
Residual tumor status      
  R0,1 39      
  R2 5 10.2 (3.07-30.7) 0.0005  4.12 (1.03-15.1) 0.044 
Adjuvant chemotherapy*      
No 24      
  Yes 15 0.90 (0.82-0.34) 0.82    
* Adjuvant chemotherapy was administered to patients with R0 or R1 resection who had poor 
prognostic factors. 
 
 Table 3  Initial recurrence site analysis based on residual tumor status and negative 
surgical margin width 
  Recurrence (n, %) P-value 
n None Local Distant 
Residual tumor status      
 R0 28 13 (46) 3 (11) 12* (43)  
 R1*** 11 4 (36) 6 (55) 1** (9) 0.008 
  Bile duct 5 1 (20) 4 (80) 0  
  Liver parenchyma 8 4 (50) 3 (38) 1 (13)  
      
Margin width in R0 cases      
   ≤ 5 mm 20 9 (45) 2 (10) 9 (45)  
  > 5 mm 8 4 (50) 1 (13) 3 (38) 0.93 
* Distant tumor sites: lymph nodes (n=3), liver (n=2), lung (n=2), bone (n=2), peritoneum 
(n=2), and unknown (n=1).  
**Liver metastasis 
*** Two R1 patients showed positivity for both bile duct and liver parenchyma 
 
 
